R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell lymphoma patients with high-risk of CNS relapse.

Trial Details

NCT ID
NCT05257018
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • R-CDOP+intrathecal MTX
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Ürümqi, Xinjiang, China|43.80096,87.60046

Key Eligibility Criteria

  • Age range from 18 to 75 years;
  • ECOG performance status: 0-2;
  • Histopathologically confirmed untreated diffuse large B-cell lymphoma (cell origin can be distinguished according to Hans algorithm) , And fulfille…
  • CNS-IPI 4-6;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →